

The COVID-19 vaccines authorized for use in Canada include: [Pfizer-BioNTech – Adult /Adolescent presentation](#), [Pfizer-BioNTech – Pediatric presentation](#), [Moderna](#), [AstraZeneca](#), [Novavax](#), and [Janssen](#). Refer to the respective product page for product specific information.

Primary Series	
Eligibility Criteria	Number of Doses
Pediatric population – 5 to 11 years of age (inclusive)	2 doses of: • Pfizer: 0.2 mL (10 mcg)
General population – 12 years of age and older	2 doses ^A of any: • Pfizer: 0.3 mL (30 mcg) - <i>preferred for 12-29 year olds</i> • Moderna: 0.5 mL (100 mcg) • Novavax (≥ 18 years of age): 0.5 mL • AstraZeneca (≥ 18 years of age): 0.5 mL OR 1 dose: Janssen (≥ 18 years of age): 0.5 mL
Moderately to severely immunosuppressed (see Appendix B) – 5 to 11 years of age	3 doses of: • Pfizer: 0.2 mL (10 mcg)
Moderately to severely immunosuppressed (see Appendix A) – 12 years of age and older	3 doses ^A of any: • Moderna: 0.5 mL (100 mcg) - <i>preferred</i> • Pfizer: 0.3 mL (30 mcg) • Novavax (≥ 18 years of age): 0.5 mL • AstraZeneca (≥ 18 years of age): 0.5 mL * For individuals who received a single dose of Janssen vaccine, a 2-dose primary series is recommended.
Booster Dose ^B	
Eligibility Criteria	Number of Doses
<ul style="list-style-type: none"> Residents of long term care (LTC), assisted living and independent living facilities, and alternate level of care clients awaiting placement in LTC Individuals 70 years of age and older 	1 dose ^A – at least 6 months after the primary series: • Pfizer: 0.3 mL (30 mcg) • Moderna: 0.5 mL (100 mcg)
<ul style="list-style-type: none"> Individuals 18-69 years of age 	1 dose ^A – at least 6 months after the primary series: • Pfizer: 0.3 mL (30 mcg) - <i>preferred for 18-29 year olds</i> • Moderna: 0.25 mL (50 mcg) - <i>preferred for 18-69 year olds who are moderately to severely immunosuppressed (see Appendix A)</i> * For individuals who received a 1-dose Janssen primary series, a booster dose is recommended at least 2 months later.
<ul style="list-style-type: none"> Individuals 12-17 years of age ^{C, D} 	1 dose – at least 6 months after the primary series: • Pfizer: 0.3 mL (30 mcg) - <i>preferred</i> • Moderna: 0.25 mL (50 mcg)

^A mRNA vaccines are the preferred COVID-19 vaccines due to the demonstrated high efficacy and effectiveness with longer term safety data. Novavax COVID-19 vaccine may be offered to individuals for whom COVID-19 mRNA vaccines are contraindicated or have been refused. A viral vector COVID-19 vaccine should only be considered when all other authorized COVID-19 vaccines are contraindicated or refused, due to the reduced effectiveness and the possible adverse effects associated with viral vector vaccines (e.g., Thrombosis with Thrombocytopenia Syndrome)

^B Pregnant persons may receive a booster dose at least 8 weeks after completion of the primary series.

^C Includes individuals who are moderately to severely immunosuppressed and received a 3-dose primary series.

^D A booster dose is particularly recommended for individuals 12-17 years of age who are at higher risk of severe illness due to COVID-19. See the [government of B.C. website](#), under “clinically extremely vulnerable criteria for youth” for further details.

Appendix A

For those 12 year of age and older, moderately to severely immunosuppressed includes:

- Have had a solid organ transplant (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).
- Since January 2020, have received treatment with any anti-CD20 agents (i.e., rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab).
- Since January 2020, have been treated with B-cell depleting agents (i.e., epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, atacicept, anti-BR3, alemtuzumab).
- Since October 2020, have received or are receiving radiation therapy for cancer.
- Since March 2020, have received or are receiving systemic therapy for solid tumours as well as hematological cancers (including chemotherapy, molecular therapy, immunotherapy, targeted therapies including CAR-T, monoclonal antibodies, hormonal therapy for cancer).
- Have combined immune deficiencies affecting T-cells, immune dysregulation (particularly familial hemophagocytic lymphohistiocytosis) or type 1 interferon defects (caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies).
- Since September 2019, have had a bone marrow or stem cell transplant or are still taking immunosuppressant medications related to transplant.
- Have a moderate to severe primary immunodeficiency which has been diagnosed by an adult or pediatric immunologist and requires ongoing immunoglobulin replacement therapy (IVIG or SCIG) or the primary immunodeficiency has a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
- On dialysis (hemodialysis or peritoneal dialysis) or have stage 5 chronic kidney disease (eGFR <15 mL/min) or have glomerulonephritis and receiving steroid treatment.
- Prior AIDS defining illness or CD4 count $\leq 200/\text{mm}^3$ or CD4 fraction $\leq 15\%$ or detectable plasma viral load since January 2021 or HIV infection and ≥ 65 years old or perinatally acquired HIV infection.
- Have taken significantly immunosuppressing drugs or treatments including at risk biologics, steroids and other agents since December 15, 2020. ^E

Appendix B

For children 5-11 years of age, moderately to severely immunosuppressed includes:

- Have had a solid organ transplant (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).
- In the last year, received systemic treatment for a haematological malignancy, including anti-CD20 or other B-cell depleting therapies.
- In the last 2 years, have had a bone marrow, stem cell transplant, CAR-T, or is still taking immunosuppressant medications.
- In the last 6 months have received anti-cancer systemic therapy for solid tumors (including but not limited to: cytotoxic chemotherapy, molecular targeted therapy, immunotherapy, monoclonal antibodies, bone modifying agents used in the setting of metastatic disease, high dose steroids [e.g. equivalent of > 20 mg/day for more than 1 month] but excluding patients only receiving hormonal or bone modifying therapy in the adjuvant setting]).
- In the last 3 months, have received or are receiving radiation therapy for cancer.
- In the past year, have received anti-CD20, B-cell depleting or similar agents. ^F
- In the last 3 months, received immunosuppressing therapies including biologic agents, oral-immune suppressing drugs, steroids (orally or by injection for a period of > 14 days), immune suppressing infusions/injections or intermittent high dose steroids administered as immune suppression prior to intravenous enzyme replacement treatment. ^F
- On dialysis (hemodialysis or peritoneal dialysis) or have stage 5 chronic kidney disease (eGFR <15 mL/min) or have glomerulonephritis and receiving steroid treatment.
- Have a primary immunodeficiency which has been diagnosed by a pediatric immunologist.
- Prior AIDS defining illness or HIV infection with prior CD4 count $\leq 200/\text{mm}^3$, prior CD4 $\leq 15\%$ or detectable plasma viral load in the last year.

^E A list of these medications can be found on the [government of B.C. website](#).

^F A list of these medications can be found on the [government of B.C. website](#).